Selective modulation of Aβ42 production in Alzheimer's disease: Non-steroidal anti-inflammatory drugs and beyond

Current Pharmaceutical Design

Volumn 12, Issue 33, 2006, Pages 4337-4355

  Leuchtenberger, Stefanie ^a   Beher, Dirk ^b,c   Weggen, Sascha ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^c AMGEN INC   (United States)

Author keywords

Amyloid precursor protein (APP); Non COX; NOTCH signaling; NSAIDs; Pro inflammatory; Transmembrane domain (TMD)

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; ARYLPROPIONIC ACID DERIVATIVE; BETA SECRETASE; BMS 299897; CELECOXIB; FENOFIBRATE; FENOPROFEN; FLURBIPROFEN; FLURIZAN; GAMMA SECRETASE INHIBITOR; GERANYLGERANYL PYROPHOSPHATE; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1BETA; MECLOFENAMIC ACID; MELOXICAM; MPC 7869; NAPROXEN; NICASTRIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; PRESENILIN 2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC SULFIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENCY; DRUG SENSITIVITY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; NEPHROTOXICITY; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SENILE PLAQUE; TREATMENT DURATION; TREATMENT OUTCOME; BIOSYNTHESIS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; PEPTIDE FRAGMENTS;

EID: 33750872524     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778793029     Document Type: Review

References (179)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-22.
2. Wancata J, Musalek M, Alexandrowicz R, Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 2003; 18: 306-13.
3. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
4. Golde TE. Alzheimer disease therapy: Can the amyloid cascade be halted? J Clin Invest 2003; 111: 11-8.
5. Selkoe DJ. Deciphering the genesis and fate of amyloid betaprotein yields novel therapies for Alzheimer disease. J Clin Invest 2002; 110: 1375-81.
6. Wilquet V, De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 2004; 14: 582-8.
7. Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta 2000; 1502: 172-87.
8. Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem 2002; 277: 44754-9.
9. Okochi M, Steiner H, Fukumori A, Tanii H, Tomita T, Tanaka T, et al. Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. EMBO J 2002; 21: 5408-16.
10. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer's disease increase production of 42- residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997; 3: 67-72.
11. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, et al. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nature Medicine 1995; 1: 1291-96.
12. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimers disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimers disease. Nat Med 1996; 2: 864-9.
13. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos LJ, Eckman C, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994; 264: 1336-40.
14. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994; 13: 45-53.
15. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996; 2: 93-5.
16. Jarrett JT, Berger EP, Lansbury PT, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693-7.
17. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996; 16: 921-32.
18. Younkin SG. The role of A beta 42 in Alzheimer's disease. J Physiol Paris 1998; 92: 289-92.
19. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-85.
20. Cumming JN, Iserloh U, Kennedy ME. Design and development of BACE-1 inhibitors. Curr Opin Drug Discov Devel 2004; 7: 536-56.
21. Harrison T, Churcher I, Beher D. gamma-Secretase as a target for drug intervention in Alzheimer's disease. Curr Opin Drug Discov Devel 2004; 7: 709-19.
22. Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 2005; 69: 689-98.
23. Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, et al. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 2005; 312: 635-43.
24. Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, et al. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5- methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 2005; 313: 902-8.
25. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76: 173-81.
26. Grimwood S, Hogg J, Jay MT, Lad AM, Lee V, Murray F, et al. Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor. Neuropharmacology 2005; 48: 1002-11.
27. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, et al. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 2003; 305: 864-71.
28. Lanz TA, Hosley JD, Adams WJ, Merchant KM. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2- (3,5-difluorophenyl)-2- hydroxyethanoyl]-N1-[(7S) -5-methyl-6-oxo -6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-Lalaninamide (LY-411575). J Pharmacol Exp Ther 2004; 309: 49-55.
29. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-58.
30. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. Embo J 2004; 23: 483-8.
31. Iwatsubo T. The gamma-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol 2004; 14: 379-83.
32. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 2000; 100: 391-8.
33. Kopan R, Ilagan MX. Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 2004; 5: 499-504.
34. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398: 518-22.
35. Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 1999; 398: 522-5.
36. Ye Y, Lukinova N, Fortini ME. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature 1999; 398: 525-9.
37. Selkoe D, Kopan R. Notch and Presenilin: Regulated Intramembrane Proteolysis Links Development and Degeneration. Annu Rev Neurosci 2003.
38. Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, et al. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem 2004; 279: 18146-56.
39. Saxena MT, Schroeter EH, Mumm JS, Kopan R. Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis. J Biol Chem 2001; 276: 40268-73.
40. Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ, D'Adamio L. Processing of beta-amyloid precursor-like protein-1 and -2 by gammasecretase regulates transcription. J Biol Chem 2002; 277: 44195-201.
41. Ikeuchi T, Sisodia SS. The Notch Ligands, Delta1 and Jagged2, Are Substrates for Presenilin-dependent "gamma -Secretase" Cleavage. J Biol Chem 2003; 278: 7751-4.
42. LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gammasecretase and release signaling fragments. J Biol Chem 2003; 278: 34427-37.
43. Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, et al. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc Natl Acad Sci USA 2003; 100: 7638-43.
44. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L, et al. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 2002; 277: 6318-23.
45. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294: 2179-81.
46. May P, Reddy YK, Herz J. Proteolytic processing of LRP mediates regulated release of its intracellular domain. J Biol Chem 2002; 20: 20.
47. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002; 21: 1948-56.
48. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, Siman R, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 2003; 114: 635-45.
49. Murakami D, Okamoto I, Nagano O, Kawano Y, Tomita T, Iwatsubo T, et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 2003; 22: 1511-6.
50. Andersson CX, Fernandez-Rodriguez J, Laos S, Baeckstrom D, Haass C, Hansson GC. Shedding and gamma-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43. Biochem J 2005; 387: 377-84.
51. Taniguchi Y, Kim SH, Sisodia SS. Presenilin-dependent "gammasecretase" processing of deleted in colorectal cancer (DCC). J Biol Chem 2003; 278: 30425-8.
52. Kim DY, Ingano LA, Kovacs DM. Nectin-1alpha, an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/gamma-secretase-like cleavage. J Biol Chem 2002; 277: 49976-81.
53. Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B, David G. Syndecan 3 intramembrane proteolysis is presenilin/ gamma-secretase-dependent and modulates cytosolic signaling. J Biol Chem 2003; 278: 48651-7.
54. Jung KM, Tan S, Landman N, Petrova K, Murray S, Lewis R, et al. Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem 2003; 278: 42161-9.
55. Gowrishankar K, Zeidler MG, Vincenz C. Release of a membrane-bound death domain by gamma-secretase processing of the p75NTR homolog NRADD. J Cell Sci 2004; 117: 4099-111.
56. Haas IG, Frank M, Veron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma-protocadherins. J Biol Chem 2005; 280: 9313-9.
57. Hambsch B, Grinevich V, Seeburg PH, Schwarz MK. {gamma}-Protocadherins, presenilin-mediated release of C-terminal fragment promotes locus expression. J Biol Chem 2005; 280: 15888-97.
58. Kim DY, Ingano LA, Carey BW, Pettingell WH, Kovacs DM. Presenilin/ gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. J Biol Chem 2005; 280: 23251-61.
59. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, et al. beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J Biol Chem 2005; 280: 23009-17.
60. Cowan JW, Wang X, Guan R, He K, Jiang J, Baumann G, et al. Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage. J Biol Chem 2005; 280: 19331-42.
61. Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, et al. L1 Is Sequentially Processed by Two Differently Activated Metalloproteases and Presenilin/{gamma}-Secretase and Regulates Neural Cell Adhesion, Cell Migration, and Neurite Outgrowth. Mol Cell Biol 2005; 25: 9040-53.
62. Conlon RA, Reaume AG, Rossant J. Notch1 is required for the coordinate segmentation of somites. Development 1995; 121: 1533-45.
63. Donoviel DB, Hadjantonakis AK, Ikeda M, Zheng H, Hyslop PS, Bernstein A. Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev 1999; 13: 2801-10.
64. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 1999; 96: 11872-7.
65. Huppert SS, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA, et al. Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1. Nature 2000; 405: 966-70.
66. Li J, Fici GJ, Mao CA, Myers RL, Shuang R, Donoho GP, et al. Positive and negative regulation of the gamma-secretase activity by nicastrin in a murine model. J Biol Chem 2003; 278: 33445-9.
67. Ma G, Li T, Price DL, Wong PC. APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development. J Neurosci 2005; 25: 192-8.
68. Serneels L, Dejaegere T, Craessaerts K, Horre K, Jorissen E, Tousseyn T, et al. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci USA 2005; 102: 1719-24.
69. Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T. Notch1 is essential for postimplantation development in mice. Genes Dev 1994; 8: 707-19.
70. Lewis HD, Perez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, et al. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages. Biochemistry 2003; 42: 7580-6.
71. Schroeter EH, Ilagan MX, Brunkan AL, Hecimovic S, Li YM, Xu M, et al. A presenilin dimer at the core of the {gamma}-secretase enzyme: Insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci USA 2003; 100: 13075-80.
72. Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002; 3: 688-94.
73. Micchelli CA, Esler WP, Kimberly WT, Jack C, Berezovska O, Kornilova A, et al. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J 2003; 17: 79-81.
74. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435: 964-8.
75. Radtke F, Wilson A, MacDonald HR. Notch signaling in T- and B-cell development. Curr Opin Immunol 2004; 16: 174-9.
76. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435: 959-63.
77. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-82.
78. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003; 278: 46107-16.
79. Walker ES, Martinez M, Brunkan AL, Goate A. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem 2005; 92: 294-301.
80. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6.
81. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
82. Golde TE. Inflammation takes on Alzheimer disease. Nat Med 2002; 8: 936-8.
83. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002; 35: 419-32.
84. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003; 327: 128.
85. in t'Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-21.
86. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-32.
87. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
88. Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. J Neurochem 2004; 91: 521-36.
89. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P. Nonsteroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets 2003; 4: 461-8.
90. Imbimbo BP. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs 2004; 13: 1469-81.
91. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gammasecretase activity. J Biol Chem 2003; 278: 31831-7.
92. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440-9.
93. Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem 2002; 83: 1009-12.
94. Peretto I, Radaelli S, Parini C, Zandi M, Raveglia LF, Dondio G, et al. Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of beta-Amyloid(1)(-)(42) Secretion. J Med Chem 2005; 48: 5705-20.
95. Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T, et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003; 278: 18664-70.
96. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, et al. Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic A{beta}42 by Inhibiting Rho. Science 2003; 302: 1215-7.
97. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, et al. Anti-Inflammatory Drug Therapy Alters {beta}-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease. J Neurosci 2003; 23: 7504-9.
98. Esselmann H, Maler JM, Dyrks T, Kochanny M, Reulbach U, Kunz N, et al. In 8th World Congress of Biological Psychiatry: Vienna, Austria, 2005.
99. Lanz TA, Fici GJ, Merchant KM. Lack of Specific Amyloid-{beta}(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures. J Pharmacol Exp Ther 2005; 312: 399-406.
100. Gasparini L, Rusconi L, Xu H, Del Soldato P, Ongini E. Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J Neurochem 2004; 88: 337-48.
101. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 2005; 11: 545-50.
102. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999; 46: 412-6.
103. Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004; 279: 43419-26.
104. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003; 278: 30748-54.
105. Oster-Granite ML, McPhie DL, Greenan J, Neve RL. Agedependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci 1996; 16: 6732-41.
106. Avramovich Y, Amit T, Youdim MB. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem 2002; 277: 31466-73.
107. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20: 5709-14.
108. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102.
109. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002; 22: 2246-54.
110. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Pereztur J, et al. Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383: 710-3.
111. Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, et al. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 2004; 165: 2197-206.
112. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004; 7: 954-60.
113. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001; 22: 983-91.
114. Falinska AM, Yates AS, Chapman PF. In 31th Annual Meeting of the Society for Neuroscience: San Diego (USA), 2001.
115. Westerman MA, Kotilinek K, Hsiao Ashe KK. In 8th International Conference on Alzheimer's Disease and Related Disorders: Stockholm (Schweden), 2002.
116. Abdel-Halim MS, Sjoquist B, Anggard E. Inhibition of prostaglandin synthesis in rat brain. Acta Pharmacol Toxicol (Copenh) 1978; 43: 266-72.
117. McEvoy GK. AHFS drug information, American Society of Health-System Pharmacists 1998.
118. Mannila A, Rautio J, Lehtonen M, Jarvinen T, Savolainen J. Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases. Eur J Pharm Sci 2005; 24: 101-5.
119. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews Cancer 2001; 1: 11-21.
120. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-72.
121. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 2000; 51: 511-23.
122. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
123. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999; 274: 27307-14.
124. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000; 97: 4844-9.
125. Kolasa T, Brooks CD, Rodriques KE, Summers JB, Dellaria JF, Hulkower KI, et al. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. J Med Chem 1997; 40: 819-24.
126. Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res 2001; 61: 4879-84.
127. Vanderhoek JY, Bailey JM. Activation of a 15-lipoxygenase/leukotriene pathway in human polymorphonuclear leukocytes by the anti-inflammatory agent ibuprofen. J Biol Chem 1984; 259: 6752-6.
128. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-45.
129. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-10.
130. Sagi SA, Weggen S, Eriksen J, Golde TE, Koo EH. The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. J Biol Chem 2003; 278: 31825-30.
131. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003; 23: 9796-804.
132. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 2004; 24: 10908-17.
133. Leuchtenberger S, Kummer MP, Kukar T, Czirr E, Teusch N, Sagi SA, et al. Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42. J Neurochem 2006; 96: 355-65.
134. Symons M, Rusk N. Control of vesicular trafficking by Rho GTPases. Curr Biol 2003; 13: R409-18.
135. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J 2000; 348 Pt 2: 241-55.
136. Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, Ostaszewski BL, et al. Purification and characterization of the human gammasecretase complex. Biochemistry 2004; 43: 9774-89.
137. Beher D, Fricker M, Nadin A, Clarke EE, Wrigley JD, Li YM, et al. In Vitro Characterization of the Presenilin-Dependent gamma-Secretase Complex Using a Novel Affinity Ligand. Biochemistry 2003; 42: 8133-42.
138. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai JY, et al. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2000; 2: 428-34.
139. Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000; 405: 689-94.
140. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE, Jr., et al. Presenilin-1 and -2 are molecular targets for gamma -secretase inhibitors. J Biol Chem 2000; 275: 34086-91.
141. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, et al. Activity-dependent isolation of the presenilin-gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci USA 2002; 99: 2720-5.
142. Kornilova AY, Bihel F, Das C, Wolfe MS. The initial substrate-binding site of {gamma}-secretase is located on presenilin near the active site. Proc Natl Acad Sci USA 2005; 102: 3230-5.
143. Tian G, Sobotka-Briner CD, Zysk J, Liu X, Birr C, Sylvester MA, et al. Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J Biol Chem 2002; 277: 31499-505.
144. Ikeuchi T, Dolios G, Kim SH, Wang R, Sisodia SS. Familial Alzheimer disease-linked presenilin 1 variants enhance production of both Abeta 1-40 and Abeta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of "gamma-secretase". J Biol Chem 2003; 278: 7010-8.
145. Steiner H, Romig H, Grim MG, Philipp U, Pesold B, Citron M, et al. The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing. J Biol Chem 1999; 274: 7615-8.
146. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 1996; 17: 181-90.
147. Berezovska O, Lleo A, Herl LD, Frosch MP, Stern EA, Bacskai BJ, et al. Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci 2005; 25: 3009-17.
148. Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004; 10: 1065-6.
149. Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL, Beyreuther K. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci USA 1999; 96: 3053-8.
150. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11.
151. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev 2002: CD003673.
152. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54: 588-93.
153. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial. Jama 2003; 289: 2819-26.
154. McGeer PL. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 2000; 17: 1-11.
155. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.
156. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A doubleblind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197-201.
157. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30: 1204-15.
158. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebocontrolled study. Lancet 2001; 358: 455-60.
159. Zandi PP, Breitner JC. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001; 22: 811-7.
160. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under-recognized public health problem. Arch Intern Med 2000; 160: 777-84.
161. Tabet N, Feldmand H. Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev 2003: CD004031.
162. Michaelis ML. Drugs targeting Alzheimer's disease: some things old and some things new. J Pharmacol Exp Ther 2003; 304: 897-904.
163. Evans AM. Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. J Clin Pharmacol 1996; 36: 7S-15S.
164. Wechter WJ. Drug chirality: on the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates. J Clin Pharmacol 1994; 34: 1036-42.
165. Geisslinger G, Lotsch J, Menzel S, Kobal G, Brune K. Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br J Clin Pharmacol 1994; 37: 392-4.
166. Leipold DD, Kantoci D, Murray ED, Jr., Quiggle DD, Wechter WJ. Bioinversion of R-flurbiprofen to S-flurbiprofen at various dose levels in rat, mouse, and monkey. Chirality 2004; 16: 379-87.
167. Nicolle MM, Prescott S, Murphy MP, Kukar T, Eriksen JL, Koo EH, et al. In 34th Annual Meeting Society for Neuroscience: San Diego, CA, 2004.
168. http://www.myriad.com/alzheimers/phase2_ad.php
169. Munoz B, Prasit P, Stock NS. (Merck & Co. I) Geminally disubstituted NSAID derivatives as Abeta42 lowering agents. WO 2004/064771.
170. Raveglia L, Peretto L, Radaelli S, Imbimbo BP, Rizzi A, Villetti G. (Ciesi Farmaceutici S.P.A.) 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases. WO 2004/074232.
171. Raveglia L, Peretto L, Radaelli S, Imbimbo BP, Rizzi A, Villetti G. (Ciesi Farmaceutici S.P.A.) 1-Phenyl-2-monoalkyl carboxylic acid derivatives for the treatment of neurodegenerative diseases. WO 2004/ 073705.
172. Beher D, Bettati M, Checksfield GD, Churcher I, Doughty VA, Oakley PJ, et al. (Merck Sharp & Dohme Limited U) Treatment for Alzheimer's disease and related conditions. WO 2005/013985.
173. Beher D, Bettati M, Churcher I, Munoz B, Prasit P, Quddus A, et al. (Merck & Co. I, Merck Sharp & Dohme Limited U) 1-Alkyl-3-thio-substituted indole-2-alkynoic acid useful for the treatment of Alzheimer's disease and related conditions. WO 2005/054193.
174. Cheng S, Comer DD, Mao L, Balow GP, Pleynet D. (Neurogenetics I) Compounds and uses thereof in modulating Abeta. WO 2004/110350.
175. Wagner SL, Kounnas MZ, Tyree CM, Cheng S, Danks AM, Ackermann EJ, et al. In 7th International Conference AD/PD: Sorrento, Italy, 2005.
176. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005; 4: 387-98.
177. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005; 11(14): 1795-804.
178. El Mouedden M, Vandermeeren M, Meert T, Mercken M. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors. Curr Pharm Des 2006; 12(6): 671-6.
179. Hajieva P, Behl C. Antioxidants as a potential therapy against age-related neurodegenerative diseases: amyloid Beta toxicity and Alzheimer's disease. Curr Pharm Des 2006; 12(6): 699-704.